Am J Ophthalmol. 1998 Oct;126(4):498-505. doi: 10.1016/s0002-9394(98)00272-4.
In a companion paper, we determined that intraocular pressure is part of the pathogenesis of normal-tension glaucoma by analyzing the effect of a 30% intraocular pressure reduction on the subsequent course of the disease. We report an intent-to-treat analysis of the study data to determine the effectiveness of pressure reduction.
One eligible eye of 145 subjects with normal-tension glaucoma was randomized either to no treatment (control) or to a 30% intraocular pressure reduction from baseline. To be eligible for randomization, the normal-tension glaucoma eyes had to show documented progression of field defects or a new disk hemorrhage or had to have field defects that threatened fixation when first presented for the study. Survival analysis compared time to progression of all randomly assigned patients during the course of follow-up from the initial baseline at randomization. In a separate analysis, data of patients developing cataracts were censored at the time that cataract produced 2 lines of Snellen visual acuity loss.
Visual field progression occurred at indistinguishable rates in the pressure-lowered (22/66) and the untreated control (31/79) arms of the study (P = .21). In an analysis with data censored when cataract affected visual acuity, visual field progression was significantly more common in the untreated group (21/79) compared with the treated group (8/66). An overall survival analysis showed a survival of 80% in the treated arm and of 60% in the control arm at 3 years, and 80% in the treated arm and 40% in the controls at 5 years. The Kaplan-Meier curves were significantly different (P = .0018). The analyses gave different results because of a higher incidence of cataract in the group that underwent filtration surgery.
The favorable effect of intraocular pressure reduction on progression of visual change in normal-tension glaucoma was only found when the impact of cataracts on visual field progression, produced largely by surgery, was removed. Lowering intraocular pressure without producing cataracts is beneficial. Because not all untreated patients progressed, the natural history of normal-tension glaucoma must be considered before embarking on intraocular pressure reduction with therapy apt to exacerbate cataract formation unless normal-tension glaucoma threatens serious visual loss.
在一篇相关论文中,我们通过分析眼压降低30%对疾病后续病程的影响,确定眼压是正常眼压性青光眼发病机制的一部分。我们报告一项意向性分析研究数据,以确定眼压降低的有效性。
145例正常眼压性青光眼患者的一只符合条件的眼睛被随机分为不治疗组(对照组)或眼压从基线降低30%的治疗组。为符合随机分组条件,正常眼压性青光眼的眼睛必须有记录的视野缺损进展或新的视盘出血,或在首次参加本研究时存在威胁固视的视野缺损。生存分析比较了所有随机分组患者从随机化初始基线开始随访期间的进展时间。在一项单独分析中,白内障导致Snellen视力下降2行时,对发生白内障患者的数据进行截尾。
在研究的眼压降低组(22/66)和未治疗对照组(31/79)中,视野进展发生率无显著差异(P = 0.21)。在白内障影响视力时对数据进行截尾的分析中,与治疗组(8/66)相比,未治疗组(21/79)视野进展明显更常见。总体生存分析显示,治疗组3年生存率为80%,对照组为60%;5年时治疗组为80%,对照组为40%。Kaplan-Meier曲线有显著差异(P = 0.0018)。由于接受滤过手术组白内障发生率较高,这些分析得出了不同结果。
仅在消除白内障(主要由手术引起)对视野进展的影响后,才发现眼压降低对正常眼压性青光眼视力变化进展有有益作用。在不产生白内障的情况下降低眼压是有益的。由于并非所有未治疗患者都会进展,因此在采用易于加重白内障形成的治疗方法降低眼压之前,必须考虑正常眼压性青光眼的自然病程,除非正常眼压性青光眼威胁到严重视力丧失。